Apyx Medical Free Cash Flow (FCF) History (APYX)
Apyx Medical reported −$9.1M in free cash flow for fiscal 2025, an increase of $9.7M from the previous fiscal year, with a free cash flow margin of −17.25%.
View full Apyx Medical company overviewApyx Medical free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$9.1M | $9.7M | — | −17.25% |
| 2024 | 2024-12-31 | −$18.8M | −$13.0M | — | −39.02% |
| 2023 | 2023-12-31 | −$5.8M | $15.5M | — | −11.05% |
| 2022 | 2022-12-31 | −$21.3M | −$10.1M | — | −47.83% |
| 2021 | 2021-12-31 | −$11.2M | $5.5M | — | −23.03% |
| 2020 | 2020-12-31 | −$16.6M | $3.1M | — | −60.07% |
| 2019 | 2019-12-31 | −$19.8M | $1.5M | — | −70.04% |
| 2018 | 2018-12-31 | −$21.2M | −$16.9M | — | −127.94% |
| 2017 | 2017-12-31 | −$4.3M | −$1.2M | — | −42.29% |
| 2016 | 2016-12-31 | −$3.1M | $3.1M | — | −35.41% |
| 2015 | 2015-12-31 | −$6.2M | −$5.2M | — | −21.03% |
| 2014 | 2014-12-31 | −$1.0M | $2.1M | — | −3.78% |
| 2013 | 2013-12-31 | −$3.1M | −$2.5M | — | −13.20% |
| 2012 | 2012-12-31 | −$588,000 | −$1.9M | — | −2.12% |
| 2011 | 2011-12-31 | $1.4M | $2.1M | — | +5.33% |
| 2010 | 2010-12-31 | −$727,000 | $1.8M | — | −3.00% |
| 2009 | 2009-12-31 | −$2.6M | — | — | −9.51% |
Apyx Medical quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$3.6M | −$2.1M | — | −25.61% |
| Q1 2026 | 2026-03-31 | −$632,000 | $125,000 | — | −5.06% |
| Q4 2025 | 2025-12-31 | −$2.8M | $377,000 | — | −14.64% |
| Q3 2025 | 2025-09-30 | −$4.1M | $538,000 | — | −31.49% |
| Q2 2025 | 2025-06-30 | −$1.5M | $3.1M | — | −13.17% |
| Q1 2025 | 2025-03-31 | −$757,000 | $5.6M | — | −8.03% |
| Q4 2024 | 2024-12-31 | −$3.2M | −$877,000 | — | −22.37% |
| Q3 2024 | 2024-09-30 | −$4.6M | −$8.1M | — | −39.98% |
| Q2 2024 | 2024-06-30 | −$4.6M | $390,000 | — | −38.01% |
| Q1 2024 | 2024-03-31 | −$6.4M | −$4.4M | — | −62.24% |
| Q4 2023 | 2023-12-31 | −$2.3M | $2.4M | — | −15.72% |
| Q3 2023 | 2023-09-30 | $3.5M | $9.1M | — | +29.41% |
| Q2 2023 | 2023-06-30 | −$5.0M | $1.3M | — | −36.91% |
| Q1 2023 | 2023-03-31 | −$2.0M | $2.8M | — | −16.40% |
| Q4 2022 | 2022-12-31 | −$4.7M | −$4.6M | — | −37.05% |
| Q3 2022 | 2022-09-30 | −$5.5M | −$1.8M | — | −60.87% |
| Q2 2022 | 2022-06-30 | −$6.3M | −$1.2M | — | −60.95% |
| Q1 2022 | 2022-03-31 | −$4.8M | −$2.6M | — | −38.40% |
| Q4 2021 | 2021-12-31 | −$118,000 | $1.3M | — | −0.70% |
| Q3 2021 | 2021-09-30 | −$3.8M | −$1.1M | — | −31.91% |
| Q2 2021 | 2021-06-30 | −$5.0M | $85,000 | — | −44.86% |
| Q1 2021 | 2021-03-31 | −$2.2M | $5.3M | — | −25.98% |
| Q4 2020 | 2020-12-31 | −$1.4M | $2.1M | — | −12.26% |
| Q3 2020 | 2020-09-30 | −$2.6M | $2.5M | — | −37.75% |
| Q2 2020 | 2020-06-30 | −$5.1M | $867,000 | — | −119.18% |
| Q1 2020 | 2020-03-31 | −$7.5M | −$2.3M | — | −150.03% |
| Q4 2019 | 2019-12-31 | −$3.5M | $14.7M | — | −41.47% |
| Q3 2019 | 2019-09-30 | −$5.1M | −$3.8M | — | −67.42% |
| Q2 2019 | 2019-06-30 | −$6.0M | −$5.2M | — | −90.04% |
| Q1 2019 | 2019-03-31 | −$5.2M | −$4.0M | — | −92.49% |
| Q4 2018 | 2018-12-31 | −$18.2M | −$18.7M | — | −311.48% |
| Q3 2018 | 2018-09-30 | −$1.3M | −$462,000 | — | −34.94% |
| Q2 2018 | 2018-06-30 | −$766,000 | $390,000 | — | −20.75% |
| Q1 2018 | 2018-03-31 | −$1.2M | $1.6M | — | −36.71% |
| Q4 2017 | 2017-12-31 | $538,000 | $1.2M | — | — |
| Q3 2017 | 2017-09-30 | −$821,000 | −$767,000 | — | −30.97% |
| Q2 2017 | 2017-06-30 | −$1.2M | −$1.0M | — | −11.80% |
| Q1 2017 | 2017-03-31 | −$2.9M | −$601,000 | — | −34.44% |
| Q4 2016 | 2016-12-31 | −$648,000 | $556,000 | — | — |
| Q3 2016 | 2016-09-30 | −$54,000 | $732,000 | — | −0.54% |
| Q2 2016 | 2016-06-30 | −$133,000 | $2.4M | — | −1.43% |
| Q1 2016 | 2016-03-31 | −$2.3M | −$243,000 | — | −29.43% |
| Q4 2015 | 2015-12-31 | −$1.2M | −$1.1M | — | −14.51% |
| Q3 2015 | 2015-09-30 | −$786,000 | −$1.3M | — | −10.05% |
| Q2 2015 | 2015-06-30 | −$2.5M | −$2.2M | — | −34.89% |
| Q1 2015 | 2015-03-31 | −$2.0M | −$921,000 | — | −33.37% |
| Q4 2014 | 2014-12-31 | −$113,000 | $1.4M | — | −1.51% |
| Q3 2014 | 2014-09-30 | $543,000 | $589,000 | — | +8.00% |
| Q2 2014 | 2014-06-30 | −$353,000 | $823,000 | — | −5.08% |
| Q1 2014 | 2014-03-31 | −$1.1M | −$740,000 | — | −17.34% |
| Q4 2013 | 2013-12-31 | −$1.5M | −$1.2M | — | −24.77% |
| Q3 2013 | 2013-09-30 | −$46,000 | $416,000 | — | −0.79% |
| Q2 2013 | 2013-06-30 | −$1.2M | −$2.1M | — | −19.46% |
| Q1 2013 | 2013-03-31 | −$384,000 | $345,000 | — | −6.74% |
| Q4 2012 | 2012-12-31 | −$293,000 | $38,000 | — | −4.29% |
| Q3 2012 | 2012-09-30 | −$462,000 | −$192,000 | — | −6.93% |
| Q2 2012 | 2012-06-30 | $896,000 | −$398,000 | −30.76% | +12.04% |
| Q1 2012 | 2012-03-31 | −$729,000 | −$1.4M | — | −10.83% |
| Q4 2011 | 2011-12-31 | −$331,000 | $353,000 | — | −5.37% |
| Q3 2011 | 2011-09-30 | −$270,000 | — | — | −4.32% |
| Q2 2011 | 2011-06-30 | $1.3M | — | — | +18.92% |
| Q1 2011 | 2011-03-31 | $662,000 | — | — | +10.76% |
| Q3 2010 | 2010-09-30 | −$684,000 | — | — | −10.52% |
Apyx Medical free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$16.6M to −$9.1M, a net increase of $7.5M. Apyx Medical's latest reported quarter, Q2 2026, generated −$3.6M in free cash flow, a decrease of $2.1M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Apyx Medical filings at SEC.gov ↗